Skip to main content

Table 3 Linear regression analysis on health-related quality of life outcomes in 252 patients with systemic lupus erythematosus in regard with disease activity age, sex and disease duration

From: Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)

Outcomes

Predictors

 

SELENA-SLEDAI, unadjusted (N = 252)

SLEDAI, adjusted for age, sex and disease duration (N = 225)

Difference in SF-36 score for a 1-point increase in SELENA-SLEDAI

95%-C.I.

p

Difference in SF-36 score for a 1-point increase in SELENA-SLEDAI

95%-C.I.

p

Physical function

−0.57

(−1.05, −0.10)

0.019

−0.66

(−1.12, −0.19)

0.006

Role physical

−1.86

(−2.63, −1.09)

<0.001

−1.85

(−2.63, −1.07)

<0.001

Bodily pain

−1.16

(−1.68, −0.64)

<0.001

−1.27

(−1.79, −0.74)

<0.001

General health

−0.31

(−0.70, 0.08)

0.12

−0.27

(−0.67, 0.13)

0.19

Vitality

−0.48

(−0.86, −0.10)

0.014

−0.46

(−0.86, −0.07)

0.022

Social function

−0.72

(−1.19, −0.25)

<0.001

−0.71

(−1.20, −0.22)

0.005

Role emotional

−1.92

(−2.73, −1.11)

<0.01

−1.86

(−2.70, −1.01)

<0.001

Mental health

−0.48

(−0.84, −0.13)

0.008

−0.46

(−0.81, −0.11)

0.011

Mental component summary

−0.31

(−0.50, −0.12)

0.002

−0.34

(−0.53, −0.15)

<0.001

Physical component summary

−0.36

(−0.57, −0.15)

0.001

−0.33

(−0.55, −0.11)

0.003

  1. SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)